Congratulations to research fellow + lab member @SimonRedaelliMD for a spotlight as young investigator in the March special issue on Intensive Care in the AJRCCM!! @ATSBlueEditor
The Blue Journal thanks Simone Redaelli, MD, for his contribution to the March 1 issue
Adjustments of Ventilator Parameters during Operating Room–to–ICU Transition and 28-Day Mortality
@SimonRedaelliMD@maxsebschaefer
https://t.co/Y55M0xp4VQ
Congratulations to lab member @dariovonwedel for a spotlight as young investigator in the March special issue on Intensive Care of the AJRCCM @ATSBlueEditor
The Blue Journal thanks Dario von Wedel for his contribution to the March 1 issue
Adjustments of Ventilator Parameters during Operating Room–to–ICU Transition and 28-Day Mortality
@dariovonwedel@maxsebschaefer
https://t.co/Y55M0xp4VQ
Adjustments of Ventilator Parameters during Operating Room–to–ICU Transition and 28-Day Mortality
When adjustments of ventilator settings lead to increased ventilation intensity, they might precipitate higher 28-day mortality
@maxsebschaefer
🔗 https://t.co/TwBqk73U57
In this study of abstracts, addition of affiliations was significantly associated with acceptance rates by a commonly used large language model, with higher tiers of institutions being associated with higher acceptance rates.
https://t.co/Sq85J578nM
I’m glad to share that our work on inflammatory subphenotypes in patients at risk of #ARDS has just been published in @yourICM
Thank you to all the people that made this achievement possible
@BIDMCAnesthesia@unimib
🫁 Inflammatory subphenotypes in pts at risk of #ARDS: potential predictive/prognostic strategy? Hyper & non-hyper-inflammatory subphenotypes may precede development, identifiable in ED & remain identifiable. Worse outcomes if hyper-inflammatory type.
🖇️ https://t.co/hpYYNP04mK
Time to rethink how we treat intraoperative hypotension?
@BIDMCAnesthesia@harvardmed
Intraoperative use of phenylephrine versus ephedrine and postoperative delirium: A multicenter retrospective cohort study https://t.co/PC8qGJCs3w
AI for prediction of treatment outcomes in breast cancer:
1. Despite the exponential increase in the number of algorithms published in breast oncology, very few are prospectively evaluated in clinical practice.
2. Using the PROBAST tool, 72% have high risk of bias.